erlotinib hydrochloride has been researched along with Inflammatory Response Syndrome, Systemic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azuma, J; Iekushi, K; Iwabayashi, M; Morishita, R; Rakugi, H; Sanada, F; Shimizu, K; Taniyama, Y | 1 |
1 other study(ies) available for erlotinib hydrochloride and Inflammatory Response Syndrome, Systemic
| Article | Year |
|---|---|
Hepatocyte growth factor inhibits lipopolysaccharide-induced oxidative stress via epithelial growth factor receptor degradation.
Topics: Animals; Aorta; Capillary Permeability; Cells, Cultured; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Hepatocyte Growth Factor; Humans; Inositol Polyphosphate 5-Phosphatases; Kidney; Lipopolysaccharides; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oxidative Stress; Phosphoric Monoester Hydrolases; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; RNA Interference; Systemic Inflammatory Response Syndrome; Transfection; Vascular Cell Adhesion Molecule-1 | 2012 |